Therapeutic options for diseases due to potential viral agents of bioterrorism

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 172-178

  Bronze, Michael S ^a   Greenfield, Ronald A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bioterrorism; Drug therapy; Post exposure prophylaxis; Smallpox; Vaccines; Viral hemorrhagic fever viruses

Indexed keywords

ADENOSYLHOMOCYSTEINASE INHIBITOR; ALPHA2B INTERFERON; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; DNA VACCINE; EBOLA VACCINE; HYPERIMMUNE GLOBULIN; IDOXURIDINE; LIVE VACCINE; METISAZONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C3; MONOCLONAL ANTIBODY KZ52; NEOPLANCIN A; PHENAZONE; PHENOTHIAZINE DERIVATIVE; PLACEBO; RIBAVIRIN; SMALLPOX VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ANTIBODY; VACCINIA ONCOLYSATE; VACCINIA VACCINE; VIDARABINE; VIRUS ANTIBODY; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BLOOD TRANSFUSION; CLINICAL TRIAL; COWPOX; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ECZEMA; ERADICATION THERAPY; GENOME ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER TOXICITY; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; POSTVACCINAL ENCEPHALITIS; PROPHYLAXIS; REVIEW; SKIN DISEASE; SMALLPOX; SMALLPOX VIRUS; VACCINATION; VACCINIA; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS VIRULENCE; YELLOW FEVER;

ANTIVIRAL AGENTS; BIOTERRORISM; HEMORRHAGIC FEVERS, VIRAL; HUMANS; IMMUNOTHERAPY; SMALLPOX; VACCINATION; VIRUS DISEASES;

EID: 0037302381     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Centers for Disease Control and Prevention: Biological and chemical terrorism: Strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Morb Mortal Wkly Rep (2000) 49(RR-4):1-14.
2. Casadevall A: Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 8(8):833-841.
3. Henderson DA, Ingelsby TV, Bartlett JG, Ascher MS, Eitzen D, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T et al: Smallpox as a biological weapon. Medical and public health management. J Am Med Assoc (1999) 281(22):2127-2137. This is a comprehensive review of smallpox focusing on its potential as a bioterrorism agent, and therapeutic and preventive strategies.
4. Meltzer MI, Damon I, LeDuc JW, Millar JD: Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis (2001) 7(6):959-969.
5. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL: Developing new smallpox vaccines. Emerg Infect Dis (2001) 7(6):920-926.
6. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, Atmar RL, Edelman R, Nolan CM, Belshe RB: Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 346(17):1265-1274.
7. Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, Rothman AL, Kennedy JS, Wolff M, Belshe RB, Ennis FA: Dose related effects of smallpox vaccine. N Engl J Med (2002) 346(17):1275-1280.
8. Breman JG, Henderson DA: Diagnosis and management of smallpox. N Engl J Med (2002) 346(17):1300-1308.
9. Nanning W: Prophylactic effect on anti-vaccinia γ-globulin against post-vaccinial encephalitis. Bull World Health Organ (1962) 27:317-324.
10. Kesson AM, Ferguson JK, Rawlison WD, Cunningham AL: Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis (1997) 25(4):911-914.
11. Centers for Disease Control & Prevention: Vaccinia (smallpox) vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mort Wkly Rep (2001) 50 (RR-10):1-25.
12. Centers for Disease Control and Prevention: Draft supplemental recommendations of the ACIP: Use of smallpox (vaccinia) vaccine. June (2002). http://www.bt.cdc.gov/agent/smallpox/vaccination/acip-guidelines.asp.
13. Kaplan EH, Craft DL, Wein LM: Emergency response to a smallpox attack: The case for mass vaccination. Proc Natl Acad Sci USA (2002) 99(16):10935-10940.
14. Kemper AR, Davis MM, Freed GL: Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract (2002) 5(2):84-90.
15. Redfield RR, Wright CD, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV). N Engl J Med (1987) 316(11):673-676.
16. Heiner GG, Fatima N, Russell PK, Haase AT, Ahmad N, Mohammed N, Thomas DB, Mack TM, Khan MM, Knatterud GL, Anthony RL et al: Field trials of methisazone as a prophylactic agent against smallpox. Am J Epidemiol (1971) 94(5):435-449.
17. De Clercq E: Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev (2001) 14(2):383-397. Excellent review of pharmacological agents with potential efficacy against smallpox. Vaccinia virus models are detailed relative to potential therapeutic uses in humans.
18. Bray M, Martinez M, Kefauver D, West M, Roy C: Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res (2002) 54(3):129-142.
19. Bauer DJ: Clinical experience with the antiviral drug marboran (1-methylisatin 3-thiosemicarbazone). Ann NY Acad Sci (1965) 130(1):110-117.
20. Rao AR, Jacobs ES, Kamalkshi S, Bradbury, Swamy A: Chemoprophylaxis and chemotherapy in Variola major. I. An assessment of CG-662 and marboran in prophylaxis of contacts of Variola major. Indian J Med Res (1969) 57(3):477-483.
21. Veckenstedt A, Zgorniak-Nowosielska I: Antiviral activity of certain isatinisothiosemicarbazones against mengo and vaccinia virus infections in mice. Acta Virol (1979) 23(1):45-51.
22. Sidwell RW, Allen LB, Khare GP, Huffman JH, Witkowski JT, Simon LN, Robins RK: Effect of 1-β-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole; ICN-1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother (1973) 3(2):242-246.
23. Neyts J, Verbeken E, De Clercq E: Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother (2002) 46(9):2842-2847.
24. Smee DF, Bailey KW, Sidwell RW: Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chem Chemother (2000) 11(4):303-309.
25. Koplan JP, Monsur KA, Foster SO, Huq F, Rahaman MM, Huq S, Buchanan RA, Ward NA: Treatment of Variola major with adenine arabinoside. J Infect Dis (1975) 131(1):34-39.
26. Monsur KA, Hossain MS, Hug F, Rahaman MM, Haque MQ: Treatment of variola major with cytosine arabinoside. J Infect Dis (1975) 131(1):40-43.
27. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother (2002) 46(5):1329-1335.
28. De Clercq E: Cidofovir in the therapy and short term prophylaxis of poxvirus infections. Trends Pharmacol Sci (2002) 23(10):456-458.
29. Neyts J, De Clercq E: Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol (1993) 41(3):242-246.
30. Smee DF, Bailey KW, Sidwell RW: Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem Chemother (2001) 12(1):71-76.
31. Kern ER, Harline C, Harden E, Keith K, Rodriquez N, Beadle JR, Hostetler KY: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother (2002) 46(4):991-995.
32. De Clercq E: Cidofovir in the treatment of poxvirus infections. Antiviral Res (2002) 55(2):1-13. A good summary of clinical trials of cidofovir in vaccinia models. Summarizes laboratory data which indicate the potential role of this agent in management of smallpox infections.
33. Meadows KP, Tyring SK, Pavia AT, Rallis TM: Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol (1997) 133(8):987-990.
34. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, Degreef H, Maes B: A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol (2001) 64(4):543-549.
35. Dixon CW: Smallpox in Tripolitania, 1946: An epidemiological and clinical study of 500 cases, including trials of penicillin treatment. J Hyg (1948) 46:351-377.
36. Kempe CH, Bowles C, Meiklejohn G, Berge TO, St Vincent, Sundara Babu BV, Govindarajan S, Ratnakannan NR, Downie AW, Murthy VR: The use of vaccinia hyperimmune γ-globulin in the prophylaxis of smallpox. Bull World Health Org (1961) 25:41-48.
37. Ramirez JC, Tapia E, Esteban M: Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 83(5):1059-1067.
38. LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB: Smallpox research activities: US interagency collaboration, 2001. Emerg Infect Dis (2002) 8(7):743-745.
39. Sutter G, Moss B: Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand (1995) 84:195-200.
40. Sugimoto M, Yamanouchi K: Characteristics of an attenuated vaccinia virus strain, LC16mo, and its recombinant virus vaccines. Vaccine (1994) 12(8):675-681.
41. McClain DJ, Harrison Y, Yeager CL, Cruz J, Ennis FA, Gibbs P, Wright MS, Summers PL, Arthur JD, Graham JA: Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis (1997) 175(4):756-763.
42. Hashizume S, Yoshizawa H, Morita M, Suzuki K: Properties of attenuated mutant vaccinia virus, LC16m8, derived from Lister strain. In: The Vaccination: Theory and Practice. Quinnan GV (Ed), International Medical Foundation of Japan, Tokyo, Japan (1975):113-124.
43. Baird J: Aftermath of a hypothetical smallpox disaster. Emerg Infect Dis (1999) 5:547-551.
44. Neff JM, Lane JM, Fulginiti VA, Henderson DA: Contact vaccinia - Transmission of vaccinia from smallpox vaccination. J Am Med Assoc (2002) 288(15):1901-1905.
45. Copeman PW, Wallace HJ: Eczema vaccinatum. Br Med J (1964) 2:906-908.
46. Neff JM, Lane JM, Pert JA, Moore R, Millar JD, Henderson DA: Complications of smallpox vaccination, I: National survey in the United States, 1963. N Engl J Med (1967) 276(3):125-132
47. Lane JM, Ruben FL, Neff JM, Millar JD: Complications of smallpox vaccination, 1968. N Engl J Med (1969) 281(22):1201-1208.
48. Douglas RG, Lynch EC, Spira M: Treatment of progressive vaccinia: Use of methisazone, vaccinia immune serum globulin, and surgical debridement. Arch Intern Med (1972) 129(6):980-983.
49. Bronze MS, Huycke MM, Machado LJ, Voskuhl GW, Greenfield RA: Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci (2002) 323(6):316-325.
50. Borio L, Inglesby T, Peters CJ, Schamljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS et al: Hemorrhagic fever viruses as biological weapons: Medical and public health management. J Am Med Assoc (2002) 287(18):2391-2405. Excellent review of hemorrhagic fever viruses, their potential as agents of bioterrorism and issues related to the management of exposed persons.
51. Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, Weld LH, Chen R, Clover RD, Deseda-Tous J, Marchessault V et al: Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mort Wkly Rep (2002) 51(RR17):1-10.
52. Centers for Disease Control and Prevention: Adverse effects associated with 17D-derived yellow fever vaccination - United States, 2001-2002. MMWR Morb Mortal Weekly Rep (2002) 51(44):989-993.
53. Martin M, Tsai TF, Cropp B, Chang GJ, Homes DA, Tseng J, Shieh W, Zakin SR, Al-Sanouri I, Cutrona AF, Ray G et al: Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases. Lancet (2001) 358(9276):98-104.
54. Maiztegui JI, McKee KT, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Birggiler AM, Levis SC, Ambrosio AM et al: Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis (1998) 177(2):277-283.
55. McKee KT: Hemorrhagic fever viruses belonging to the families Arenaviridae, Filoviridae, and Bunyaviridae. In: Infectious Diseases, 2nd Edition. Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders Company, PA, USA (1998):2249-2265.
56. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick B: Effective vaccine for Lassa fever. J Virol (2000) 74(15):6777-6783.
57. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR: Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: Protection in mice requires CD4+ T-cells. J Virol (2002) 76(18):9176-9185.
58. Wilson JA, Hart MK: Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for viral nucleoprotein. J Virol (2001) 75(6):2660-2664.
59. Wilson JA, Bray M, Bakken R, Hart MK: Vaccine potential of Ebola virus VP24, VP30, VP35 and VP40 proteins. Virology (2001) 286(2):384-390.
60. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C: DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology (1998) 246(1):134-144.
61. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ: Immunization for Ebola virus infection. Nat Med (1998) 4(1):37-42.
62. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 408(6812):605-609.
63. Gilligan KJ, Geisbert JB, Jahrling PB, Anderson K: Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. In: Vaccines 97. Brown F, Burton D, Doherty J, Mekalanos J, Norrby E (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (1997):87-92.
64. Andrei G, De Clercq E: Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res (1993) 22(1):45-75.
65. Parren PWHI, Giesbert TW, Maruyama T, Jahrling PB, Burton DR: Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 76(12):6408-6412.
66. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, LeDuc JW, Peters CJ: Evaluation of immune globulin and recombinant interferon α2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 179(Suppl 1):224-234.
67. Jahrling PB, Peters CJ: Passive antibody therapy of Lassa fever in cynomolgus monkeys: Importance of neutralizing antibody and Lassa virus strain. Infect Immun (1984) 44(2):528-533.
68. Enria DA, Briggiler AN, Fernandez NJ, Levis SC, Maiztegui JI: Importance of dose of neutralising antibodies in treatment of Argentine hemorrhagic fever with immune plasma. Lancet (1984) 4(8397):255-256.
69. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, Huggins JW, Schmidt JJ, LeDuc JW, Peters CJ: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 11:135-140.
70. Maiztegui JI, Fernandez NJ, De Damilano AJ: Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet (1979) 2(8154):1216-1217.
71. Mupapa KM, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 179(Suppl 1):18-23.
72. Candurra NA, Maskin L, Damonte EB: Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res (1996) 31(3):149-158.
73. Ponzinibbio C, Gonzalez P, Laguens RP: Protective effect of low-dose of cyclophosphamide in experimental infection of guinea pigs with Junin virus. J Med Virol (1989) 29(2):146-151.
74. Huggins J, Zhang ZX, Bray M: Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis (1999) 179(Suppl 1):240-247.
75. Bray M, Driscoll J, Huggins JW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res (2000) 45(2):135-147.
76. Huggins JW: Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis (1989) 11(Suppl 4):750-761. Comprehensive review of the role of ribavirin in the treatment of hemorrhagic fever virus infections.
77. Weissenbacher MC, Calello MA, Colillas OJ, Rondinone SN, Frigerio MJ: Argentine hemorrhagic fever: A primate model. Intervirology (1979) 11(6):363-365.
78. Huggins JW, Jahrling P, Kende M, Canonico PG: Efficacy of ribavirin against virulent RNA virus infections In: Clinical Applications of Ribavirin. Smith RA, Knight V, Smith JAD (Eds), Academic Press, Orlando, FL, USA (1984):49-63.
79. Jahrling PB, Peters CJ, Stephen EL: Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis (1984) 149(3):420-427.
80. Kenyon RH, Canonico PG, Green DE, Peters CJ: Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother (1986) 29(3):521-523.
81. McKee KT, Huggins JW, Trahan CJ, Mahlandt BG: Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Antimicrob Agents Chemother (1988) 32(9):1304-1309.
82. Kilgore PE, Ksiazek TG, Rollins PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ: Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis (1997) 24(4):718-722.
83. Blendon RJ, DesRochers CM, Benson JM, Herrmann MJ, Taylor-Clark K, Weldon KJ: The public and the smallpox threat. January (2003) http://www.nejm.org
84. Sepkowitz KA: How contagious is vaccinia? January (2003) http:www.nemj.org